Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs)

被引:150
作者
Maass, David R.
Sepulveda, Jorge
Pernthaner, Anton
Shoemaker, Charles B. [1 ]
机构
[1] Tufts Cummings Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA
[2] Victoria Univ Wellington, Sch Biol Sci, Wellington, New Zealand
[3] AgRes Grasslands, Hopkirk Res Inst, Palmerston North, New Zealand
关键词
recombinant antibody; VHH; HCAb; camelid; alpaca; TNF;
D O I
10.1016/j.jim.2007.04.008
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant single domain antibody fragments (VHHs) that derive from the unusual camelid heavy chain only IgG class (HCAbs) have many favourable properties compared with single-chain antibodies prepared from conventional IgG. As a result, VHHs have become widely used as binding reagents and are beginning to show potential as therapeutic agents. To date, the source of VHH genetic material has been camels and llamas despite their large size and limited availability. Here we demonstrate that the smaller, more tractable and widely available alpaca is an excellent source of VHH coding DNA. Alpaca sera IgG consists of about 50% HCAbs, mostly of the short-hinge variety. Sequencing of DNA encoding more than 50 random VHH and hinge domains permitted the design of PCR primers that will amplify virtually all alpaca VHH coding DNAs for phage display library construction. Alpacas were immunized with ovine tumour necrosis factor a (TNF alpha) and a VHH phage display library was prepared from a lymph node that drains the sites of immunizations and successfully employed in the isolation of VHHs that bind and neutralize ovine TNF alpha. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:13 / 25
页数:13
相关论文
共 40 条
[1]   Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders [J].
Abuzakouk, M ;
Feighery, C ;
Jackson, J .
BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2002, 59 (03) :173-179
[2]   Development of mouse Hybridomas by fusion of myeloma cells with lymphocytes derived from spleen, lymph node, and bone marrow [J].
Basalp, A ;
Yücel, F .
HYBRIDOMA AND HYBRIDOMICS, 2003, 22 (05) :329-331
[3]   Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids [J].
Daley, LP ;
Gagliardo, LF ;
Duffy, MS ;
Smith, MC ;
Appleton, JA .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (03) :380-386
[4]   Antibody repertoire development in camelids [J].
De Genst, E ;
Saerens, D ;
Muyldermans, S ;
Conrath, K .
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2006, 30 (1-2) :187-198
[5]   Canonical antigen-binding loop structures in immunoglobulins: More structures, more canonical classes? [J].
Decanniere, K ;
Muyldermans, S ;
Wyns, L .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 300 (01) :83-91
[6]   Single-domain antibody fragments with high conformational stability [J].
Dumoulin, M ;
Conrath, K ;
Van Meirhaeghe, A ;
Meersman, F ;
Heremans, K ;
Frenken, LGJ ;
Muyldermans, S ;
Wyns, L ;
Matagne, A .
PROTEIN SCIENCE, 2002, 11 (03) :500-515
[7]   COMPARISON OF INVITRO-CELL CYTO-TOXIC ASSAYS FOR TUMOR NECROSIS FACTOR [J].
FLICK, DA ;
GIFFORD, GE .
JOURNAL OF IMMUNOLOGICAL METHODS, 1984, 68 (1-2) :167-175
[8]   Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae [J].
Frenken, LGJ ;
van der Linden, RHJ ;
Hermans, PWJJ ;
Bos, JW ;
Ruuls, RC ;
de Geus, B ;
Verrips, CT .
JOURNAL OF BIOTECHNOLOGY, 2000, 78 (01) :11-21
[9]   A CONVENIENT ENZYME-LINKED IMMUNOSORBENT-ASSAY FOR TESTING WHETHER MONOCLONAL-ANTIBODIES RECOGNIZE THE SAME ANTIGENIC SITE - APPLICATION TO HYBRIDOMAS SPECIFIC FOR THE BETA-2-SUBUNIT OF ESCHERICHIA-COLI TRYPTOPHAN SYNTHASE [J].
FRIGUET, B ;
DJAVADIOHANIANCE, L ;
PAGES, J ;
BUSSARD, A ;
GOLDBERG, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 1983, 60 (03) :351-358
[10]   Selection and identification of single domain antibody fragments from camel heavy-chain antibodies [J].
Ghahroudi, MA ;
Desmyter, A ;
Wyns, L ;
Hamers, R ;
Muyldermans, S .
FEBS LETTERS, 1997, 414 (03) :521-526